State of New Jersey Common Pension Fund D Acquires 6,660 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

State of New Jersey Common Pension Fund D grew its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 11.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 64,068 shares of the life sciences company’s stock after acquiring an additional 6,660 shares during the period. State of New Jersey Common Pension Fund D owned 0.08% of Integra LifeSciences worth $2,790,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in IART. Wedge Capital Management L L P NC increased its stake in shares of Integra LifeSciences by 1.7% in the fourth quarter. Wedge Capital Management L L P NC now owns 109,767 shares of the life sciences company’s stock worth $4,780,000 after purchasing an additional 1,832 shares in the last quarter. Duality Advisers LP increased its stake in shares of Integra LifeSciences by 32.7% in the fourth quarter. Duality Advisers LP now owns 29,432 shares of the life sciences company’s stock worth $1,282,000 after purchasing an additional 7,252 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of Integra LifeSciences by 32.3% in the fourth quarter. Handelsbanken Fonder AB now owns 12,302 shares of the life sciences company’s stock worth $536,000 after purchasing an additional 3,000 shares in the last quarter. Signaturefd LLC increased its stake in shares of Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after purchasing an additional 415 shares in the last quarter. Finally, Cooke & Bieler LP increased its stake in shares of Integra LifeSciences by 4.4% in the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after purchasing an additional 120,410 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. JMP Securities reduced their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective for the company in a research note on Wednesday, April 3rd. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Finally, Truist Financial cut their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $44.89.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $29.24 on Tuesday. Integra LifeSciences Holdings Co. has a 52 week low of $27.18 and a 52 week high of $56.21. The stock has a market capitalization of $2.30 billion, a P/E ratio of 35.23, a PEG ratio of 0.85 and a beta of 1.12. The firm has a fifty day simple moving average of $35.02 and a two-hundred day simple moving average of $38.71. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. During the same period in the previous year, the business earned $0.94 earnings per share. The business’s quarterly revenue was down .3% on a year-over-year basis. On average, analysts expect that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.